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inﬂiximab. METHODS: Thirty one gastroenterologists from
southeast Brazil prospectively evaluated all their Crohn’s disease
patients during two months. They used a structured question-
naire speciﬁcally developed to evaluate resource use by patients
with Crohn’s disease. RESULTS: A total of 118 patients with
moderate and severe disease were evaluated during 2 months.
The patients average age was 30 years and the mean body weight
was 62 kg. Fourteen patients were using inﬂiximab. The com-
parison among inﬂiximab patients and standard care patients
showed that 60.6% of the standard care patients needed hospi-
talization and only 21.4% of the inﬂiximab patients needed
hospitalization (p = 0.005). The main reason for hospitalization
among the standard care patients was due to anal ﬁstula, and
among the inﬂiximab patients, was due to anemia/hemorrhage.
CONCLUSION: The use of inﬂiximab in the management of
moderate and severe Crohn’s disease can be contributive to
reduction of the need of hospitalization among these patients.
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OBJECTIVE: To compare the cost-effectiveness (CE) of natali-
zumab (NAT) to FDA-approved tumor-necrosis factor alpha
inhibitors (anti-TNFa) in Crohn’s disease (CD). METHODS:
Decision analysis was used to model treatment for patients with
moderate-to-severe CD (Crohn’s Disease Activity Index scores
220 and <450). Patients are assumed to have failed treat-
ment with corticosteroids, immunomodulators, and anti-TNFa
therapy. The model includes an induction phase followed by a
two year maintenance phase comparing NAT 300 mg, inﬂiximab
(INF) 5 mg/kg or 10 mg/kg, and adalimumab (ADA) 40 mg
every other week or weekly. At the end of induction and each of
the four six-month maintenance cycles, patients enter one of
three efﬁcacy states (remission, response, nonresponse) that are
estimated from phase III clinical studies and NAT clinical data.
Total costs associated with each comparator agent are composed
of pharmacy and medical costs derived from published price lists
and analyses of CD claims from a database assembled by Health
Benchmarks International. Drug costs for INF and ADA were
weighted by dose based upon the distribution observed in pub-
lished phase IV studies. RESULTS: Over the two year mainte-
nance period, NAT patients on average were estimated to be in
remission for 0.41 years versus 0.22 and 0.26 for those receiving
INF and ADA, respectively. Average total costs over induction
and maintenance were predicted to be $62,377 (NAT), $55,195
(INF), and $56,654 (ADA). NAT was associated with 13% and
10% increases in total cost compared to INF and ADA, but
resulted in 86% and 57% increases in remission duration over
the comparators, respectively. The CE ratio for NAT relative to
ADA and INF remained insensitive to increases in NAT-related
costs (up to $36,000) or decreases in NAT efﬁcacy (up to -25%).
CONCLUSION: This model, based on estimates from the avail-
able published literature, projected NAT to be the most cost-
effective treatment alternative for patients who had failed prior
anti-TNFa therapy.
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OBJECTIVE: Recombinant factor VIIa, an expensive coagula-
tion factor, was previously utilized pre-operatively at UC San
Diego Medical Center (UCSDMC) to reduce blood loss during
Orthotopic Liver Transplant (OLT). Recent large randomized,
controlled clinical trials have demonstrated a lack of efﬁcacy and
a potential risk of thromboembolic complications. As a result,
use of recombinant factor VIIa for bleeding prophylaxis in OLT
was discouraged due to compromised cost-effectiveness. This
change in practice warranted validation through pharmacoeco-
nomic outcomes research. METHODS: A single-center, retro-
spective review was performed to determine if the change in
UCSDMC OLT guidelines resulted in negative outcomes. The
primary outcome measure was the volume of blood products
required during OLT. Secondary outcomes included total cost of
care, operating room time, LOS, and thromboembolic events.
RESULTS: 119 liver transplant recipients were included in the
analysis. There was no signiﬁcant difference in the primary
outcome of blood product requirement. Patients receiving factor
VIIa failed to demonstrate any statistically signiﬁcant reduction
in need for PRBC 13.8 vs 13.4 units (p = 0.9), FFP 11.3 vs 15.6
(p = 0.2), or PLT 4 vs 6.6 (p = 0.08) when compared to controls.
The secondary outcome measurements also failed to reach sta-
tistical signiﬁcance, including LOS 23 vs 15 days (p = 0.17),
blood costs (p = 0.92), surgical costs (p = 0.69), and total cost of
care (p = 0.15). Two patients developed hepatic artery thrombo-
sis in the treatment group compared to one patient in the control
group. As measured by the Scientiﬁc Registry of Transplant
Recipients (SRTR), no signiﬁcant changes in liver transplant
patient or graft survival were noted. An 83% reduction average
recombinant factor VIIa use during OLT has been demonstrated,
resulting in annual savings of $170 K. CONCLUSION: Recom-
binant factor VIIa use for reduction of blood product require-
ments in OLT has not been demonstrated to be cost-effective and
may be associated with a risk of thromboembolic events.
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OBJECTIVE: Associated with no screening, H. pylori serology
screening, and the 13C-Urea breath test (UBT) for gastric cancer
in Chinese. METHODS: A Markov model simulation was
carried out in Singaporean Chinese at age of 40 years
(n = 478,500) from the perspective of public health care provid-
ers. The main outcome measures were costs, number of gastric
cancer cases prevented, life years saved, quality-adjusted life-
years (QALYs) gained from the screening age to death, and
incremental cost-effectiveness ratios (ICERs), which were com-
pared among the three strategies. The uncertainty surrounding
ICERs was addressed by scenario analyses and probabilistic sen-
sitivity analysis using Monte Carlo simulation. RESULTS: The
ICER of serology screening versus no screening was $25,881 per
QALY gained (95% conﬁdence interval (95% CI): $5700 to
$120,000). The ICER of UBT versus no screening was $53,602
per QALY gained (95% CI: $16,000 to $230,000). ICER of UBT
versus serology screening was $470,000 per QALY gained, for
which almost all random samples of the ICERs distributed above
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$50,000 per QALY. CONCLUSION: It cannot be conﬁdently
concluded that either H. pylori screening was a cost-effective
strategy compared to no screening in all Chinese at age of 40
years. Nevertheless, serology screening has demonstrated much
more potentiality to be a cost-effective strategy, especially in the
population with higher gastric cancer prevalence.
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OBJECTIVE: To develop a claims-based Markov model for
Crohn’s disease (CD) based on the American College of Gastro-
enterology (ACG) criteria. METHODS: A Markov model was
developed using disease states as deﬁned by ACG CD practice
guidelines. The study sample consisted of unique individuals18
years old from the Medstat Marketscan databases (Medicare and
Commercial) with3 years of continuous enrollment from 2000–
2005, and with an ICD-9 diagnosis code of 555.xx. Patients were
classiﬁed as severe-fulminant, moderate-severe, mild-moderate,
or remission based on the ACG criteria. Patient exposure was
divided into six month intervals, starting on ﬁrst day of exposure.
For each interval, disease state was deﬁned according to the most
severe disease activity. Transition probabilities between disease
states were calculated based on movement from one six month
period to the next. Costs of disease states were calculated using
mean per member per month (PMPM) medical claim costs, and
the model was run separately for males and females due to
differences in life expectancy, assuming 30 years old at start.
Quality-adjusted life year (QALY) estimates were obtained from
the literature. RESULTS: There were 23,419 unique individuals,
with 198,497 eligible 6-month intervals. The distribution of
disease states were: remission (99,584; 50.2%), mild-moderate
(24,788; 12.5%), moderate-severe (56,686; 28.6%), severe-
fulminant (17,439; 8.8%). Model results for both males and
females showed that, as disease severity increased, cost per QALY
also increased. Cost per QALY for mild-moderate disease in males
was $4,310 whereas for severe-fulminant disease, it was $68,538.
Results were similar for females ($4,311 vs. $68,643).CONCLU-
SION: Results of this model indicate that cost of CD increases as
disease severity increases. In addition, although less time is spent
in the severe disease state, the cost per QALYwas high, suggesting
that therapies that can keep patients in other disease states may
prove to be beneﬁcial.
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OBJECTIVE: To assess utilization and costs of health care ser-
vices for patients diagnosed with gastroesophageal reﬂux disease
(GERD) that were dispensed once (QD) vs. twice (BID) daily
PPIs. METHODS: Employing Thomson’s MarketScan Database,
GERD patients 18+ years of age with 1+ PPI dispensed, but had
no esophagitis or Barrett’s esophagus diagnosed during 2003–
2004 were selected. The date of the ﬁrst observed PPI was con-
sidered as the index date. Frequency of PPI dosing (QD vs. BID)
was assessed from pharmacy claims. Differences in total and
GERD-related costs by cohort for the 12-month period following
the index date were assessed using multivariate regression,
adjusting for demographic and clinical characteristics (age,
gender, region, Charlson comorbidity score [CCS], pre-index
diagnosis of esophageal stricture or hemorrhage [ESH], and pre-
index use of PPIs). RESULTS: A total of 219,365 GERD patients
on QD PPI therapy and 23,011 patients on BID PPI therapy were
identiﬁed. The cohorts were similar in age, but the QD cohort
had a larger proportion of males (41% vs. 37%, p < 0.01). Mean
CCS was higher in the BID cohort (1.2 vs. 1.0, p < 0.01). A
higher proportion of BID patients had pre-index ESH diagnosed
(4% vs.3%, p < 0.01) and PPI’s dispensed (58% vs. 47%,
p < 0.01). In the 12-month follow up period, the mean number of
ofﬁce visits was higher among BID patients (14.5 vs. 12.4,
p < 0.01). Total health care payments were about $2900 higher
for BID patients ($11,102 vs. $8,169, p < 0.01), 55% of which
were payments for services. GERD-related costs were about
$750 higher for BID patients ($1941 vs. $1187, p < 0.01). On an
adjusted basis, total and GERD-related payments were approxi-
mately $1500 and $450 higher among the BID cohort. CON-
CLUSION: Findings indicate that patients diagnosed with GERD
who receive BID PPI therapy incur more and GERD-related
health care resource utilization and plan payments relative to
those on QD therapy.
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OBJECTIVE: Both constipation (C) and irritable bowel syn-
drome plus C (IBS+C) are known to be very costly. However, it is
unknown whether the costs of C are driven by the same factors
that drive the costs of IBS+C. We aimed to assess the cost of
illness (COI) for C without and with IBS (IBS+C) by point of
service. METHODS: A retrospective analysis was conducted
using multiple US-based employers’ health claims data from
2001–2005. Data included medical, pharmacy, payroll, and
demographics. ICD-9 Codes were used to include employees in
the C cohort: 564.0 (Constipation), 564.00 (Unspeciﬁed), 564.01
(Slow Transit), and 564.09 (Other). Employees with C and an
ICD-9 for IBS (564.1x) at any time were included in the IBS+C
cohort. Propensity-scores based on demographics, job-related
variables, region, existence of medical claims, and Charlson
Comorbidity Index Score were used to match ﬁve C to each
IBS+C cohort employee. For both cohorts, the index date was the
date of the ﬁrst claim for the condition. Per member per month
(PMPM) costs (adjusted to 2006 US$) were compared for each
category based on claims from: doctor’s ofﬁce, inpatient hospital,
outpatient hospital/clinic, emergency department (ED), labora-
tory, other locations, and pharmacy. Costs were compared
between groups before diagnosis, after diagnosis, and change
(before-after). RESULTS: Data were available for 203 persons
with IBS+C and 1015 propensity-score-matched C subjects.
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